Hepatocellular carcinoma (HCC) is the most common type of liver cancer and is the second cause of death due to malignancy in the world. The treatment of HCC is complex and includes potentially curative and palliative approaches. However, both curative and palliative treatments for HCC are often associated with a not-completely favorable safety/efficacy ratio. Therefore, other treatment options appear necessary in clinical practice. Transarterial radioembolization has shown a promising efficacy in terms of disease control and is associated with a good safety profile. This review discusses the use of transarterial radioembolization in HCC, with a focus on the clinical aspects of this therapeutic strategy.
Transarterial radioembolization for hepatocellular carcinoma: a review / Sacco, R; Conte, C; Tumino, E; Parisi, G; Marceglia, S; Metrangolo, S; Eggenhoffner, R; Bresci, G; Cabibbo, G; Giacomelli, L.. - In: JOURNAL OF HEPATOCELLULAR CARCINOMA. - ISSN 2253-5969. - 3:(2016), pp. 25-29. [10.2147/JHC.S50359]
Transarterial radioembolization for hepatocellular carcinoma: a review
Conte C;
2016-01-01
Abstract
Hepatocellular carcinoma (HCC) is the most common type of liver cancer and is the second cause of death due to malignancy in the world. The treatment of HCC is complex and includes potentially curative and palliative approaches. However, both curative and palliative treatments for HCC are often associated with a not-completely favorable safety/efficacy ratio. Therefore, other treatment options appear necessary in clinical practice. Transarterial radioembolization has shown a promising efficacy in terms of disease control and is associated with a good safety profile. This review discusses the use of transarterial radioembolization in HCC, with a focus on the clinical aspects of this therapeutic strategy.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
